

FibroBiologics files a U.S. patent application for engineered cell technology designed to supply continuous GLP-1 therapy internally.
You can purchase shares of FibroBiologics (NASDAQ:FBLG) through any online brokerage.
Other companies in FibroBiologics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
FibroBiologics has a consensus price target of $188.67.
The stock price for FibroBiologics (NASDAQ: FBLG) is $0.937 last updated October 29, 2026 at 9:30 AM EDT.
There are no upcoming dividends for FibroBiologics.
FibroBiologics does not have any upcoming earnings scheduled.
There is no upcoming split for FibroBiologics.
FibroBiologics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
FibroBiologics Inc a clinical-stage biotechnology company focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with unmet medical needs, including wound healing, multiple sclerosis, or MS,...